Related Experiment Videos
[Platelet antiaggregants and atheromatous arteriopathy of the lower limbs]
H Lévesque1, N Cailleux, H Courtois
1Département de médecine interne, CHU de Rouen, hôpital de Boisguillaume, France.
Insights
Antiplatelet therapy, primarily aspirin, significantly lowers vascular death and events in high-risk patients. It is not clearly indicated for primary prevention but is effective for various vascular conditions.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Preventive Cardiology
Context:
- Antiplatelet therapy is crucial for managing vascular diseases.
- Patients with acute myocardial infarction, stroke, and peripheral arteriopathy are key populations.
- Identifying optimal antiplatelet strategies remains an ongoing research area.
Purpose:
- To summarize the efficacy of antiplatelet therapy in reducing vascular events.
- To evaluate the role of antiplatelet agents across various patient groups and conditions.
- To assess the evidence for antiplatelet therapy in primary prevention.
Summary:
- Antiplatelet therapy, predominantly aspirin, substantially reduces vascular death and events in patients with acute myocardial infarction, prior myocardial infarction, unstable angina, stroke, or transient ischemic attack.
- Studies confirm its benefit in peripheral arteriopathy, reducing vascular occlusions in intermittent claudication and post-intervention settings (grafts, implants, angioplasty).
- Efficacy is consistent across demographics (age, sex, diabetic, hypertensive status) in high-risk patients, but evidence for primary prevention is lacking. Medium-dose aspirin (75-325 mg/d) for long-term use is the most researched regimen.
Impact:
- Provides evidence-based guidance on the use of antiplatelet therapy in secondary vascular prevention.
- Highlights the limitations of antiplatelet therapy in primary prevention, guiding clinical decision-making.
- Establishes medium-dose aspirin as a well-studied and effective antiplatelet regimen for vascular risk reduction.
Abstract:
Antiplatelet therapy (chiefly aspirine alone) greatly reduces the risk of vascular death and vascular events in patients with acute myocardial infarction, past history of myocardial infarction, unstable angina, stroke or transient ischaemic attack, and also in the large categories of patients at increased risk of occlusive vascular diseases. Studies of patients with peripheral arteriopathy demonstrate that antiplatelet therapy significantly reduces the risk of vascular occlusions in patients with intermittent claudication or with saphenous vein grafts or prosthetic implants or angioplasty for lower limb diseases. In trials in high risk patients where patients data were available, antiplatelet therapy produces a similar effect in middle age or old age, in men or women, in diabetic and non-diabetic or in hypertensive or normotensive patients. There is no clear evidence that antiplatelet therapy is indicated in primary prevention. Medium dose aspirin (75-325 mg/d), probably for indefinite continuation, is the most widely tested antiplatelet regimen.